EGFR and non-small cell lung carcinoma: The phase III ADAURA trial demonstrated the efficacy of 3-year osimertinib in patients with resected stage IB-IIIA (TNM7) NSCLC harboring a common EGFR mutation (exon 19 deletion or L858R point-mutation).